Company intelligence / Profile preview

Forward Pharma

Ownership: Private
Employees: ~4
Development stage: Other

Overview

Forward Pharma developed a proprietary formulation of dimethyl fumarate for inflammatory and neurological conditions. The company granted an irrevocable license to all its intellectual property to Biogen in exchange for a $1.25 billion payment in February 2017. It returned most proceeds to shareholders and began solvent liquidation in early 2025. The company may receive future royalties from Biogen on sales outside the U.S., depending on European patent outcomes. No ongoing R&D or clinical programs.

Therapeutic areas: DermatologyImmunologyNeurology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

5 assets

FP187-V2B

4 more assets in the full pipeline.

Request access →

Partnerships

Biogen (licensee of all IP)

Beyond the preview

Go deeper on Forward Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Forward Pharma.

Explore the full profile